J.P. Morgan is out with its report today on Onyx Pharmaceuticals ONXX, maintaining Overweight.
In its report, J.P. Morgan writes, "We have an OW rating on ONXX based on attractive growth driven by the
company's existing and late-stage product portfolio. The company has an established oncology product in Nexavar (renal and liver cancer), the main value contributor, that has significant growth opportunities ex-US and with late stage initiatives to expand into multiple indications (NSCLC, thyroid and breast cancer)."
J.P. Morgan maintains $44 PT on ONXX.
Shares of ONXX closed Wednesday at $30.37, down 3.71% from Tuesday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in